Hospira Vinorelbine Tartrate for Injection 50 mg/5 mL vial

Country: Australia

Language: English

Source: Department of Health (Therapeutic Goods Administration)

Active ingredient:

vinorelbine tartrate, Quantity: 13.85 mg/mL

Available from:

Hospira Australia Pty Ltd

INN (International Name):

Vinorelbine tartrate

Pharmaceutical form:

Injection

Composition:

Excipient Ingredients: water for injections

Administration route:

Intravenous

Units in package:

1 x 5 mL vial

Class:

Medicine Listed (Export Only)

Prescription type:

Not scheduled. Not considered by committee

Therapeutic indications:

Vinorelbine tartrate is indicated in the treatment of advanced non-small cell lung cancer (NSCLC), as a single agent or in combination. Vinorelbine tartrate is also indicated for the treatment of patients with metastatic breast cancer who have failed standard first-line chemotherapy for metastatic disease. In addition, vinorelbine tartrate is indicated for the treatment of patients with metastatic breast cancer who have relapsed within 6 months of anthracycline-based adjuvant therapy.

Product summary:

Visual Identification: A clear, colourless to pale yellow solution & free from visible particulates; Container Type: Vial; Container Life Time: 2 Years; Container Temperature: Store at 2 to 8 degrees Celsius

Authorization status:

Licence status A

Authorization date:

2008-05-05